Company profile
Haemair | Product Development for Medical Devices
Developing Life-saving Technology Our mission our skills Haemair has created a range of related technologies built on skills in the physical and chemical properties of blood. All have the objective of saving and improving lives in a cost-effective manner. Our focus is on developing and commercializing these technologies; we are seeking collaborators to work... View Article
Updated 06 Jun 2026 16:52
Financial period: 1 Jun 2024 to 31 May 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0NDg5OTU4MmFkaXF6a2N4
Published 26 Nov 2024 09:54
AA | Transaction MzQzODU1Mjk2OWFkaXF6a2N4
Published 07 Oct 2024 08:15
CS01 | Transaction MzQzMzYyMjQ2M2FkaXF6a2N4
Published 28 Aug 2024 10:46
Company registered at Companies House
1 Oct 2020 to 30 Sep 2021
Covid-19 attacks both the lungs and the kidneys and many patients suffer with both simultaneously. Haemair's novel integrated life support system treats both lung disease and kidney disease in one compact unit. Currently, for those suffering lung disease, the most effective treatment is Extracorporeal Life Support (ECLS). ECLS takes blood from the patient...
1 Apr 2015 to 31 Mar 2018
Respiratory problems cost the NHS over £2,500 million/annum. The project aims to deliver safe effective Extracorporeal Membrane Oxygenation with reduced risk of blood clots that will improve lives and reduce these costs. Current alternatives have a propensity to cause blood clots and consequently require high levels of anticoagulation. This anticoagulatio...
